Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

Eli Lilly and Company (NYSE: LLY) has entered into a definitive agreement to acquire Kelonia Therapeutics, Inc., a clinical-stage biotechnology firm, for a total deal value of up to $7 billion. This transaction includes an upfront payment of $3.25 billion, with additional contingent payments tied to the achievement of specific clinical, regulatory, and commercial milestones. The acquisition is anticipated to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions.

Kelonia Therapeutics has developed a proprietary in vivo gene placement system, known as iGPS®, which utilizes engineered lentiviral particles to deliver gene therapies directly into T-cells within the body. This innovative approach allows for the generation of chimeric antigen receptor T-cell (CAR-T) therapies that target diseases such as multiple myeloma. Kelonia's lead program, KLN-1010, is currently undergoing Phase 1 clinical trials for relapsed/refractory multiple myeloma, with early clinical data recently showcased at the 2025 American Society of Hematology Annual Meeting, indicating promising tolerability and potential efficacy.

The strategic rationale behind Lilly's acquisition of Kelonia lies in the enhancement of its genetic medicine capabilities. By integrating Kelonia's advanced in vivo gene delivery technology, Lilly aims to simplify the manufacturing process of CAR-T therapies, which have historically been complex, costly, and limited in accessibility. The potential of KLN-1010 to provide a one-time treatment option for multiple myeloma patients could significantly improve patient outcomes while reducing the barriers associated with traditional CAR-T therapies.

The biotechnology sector is witnessing a surge in interest and investment in genetic medicine, particularly in the development of innovative therapies for hematologic malignancies. As major pharmaceutical companies increasingly seek to expand their portfolios in this area, Lilly's acquisition of Kelonia positions it strategically to capitalize on the growing demand for advanced cancer therapies. The integration of Kelonia's technology may also pave the way for Lilly to explore applications beyond multiple myeloma, potentially transforming treatment paradigms across various cancers and serious diseases.

In summary, the acquisition of Kelonia Therapeutics by Eli Lilly represents a significant move within the biotechnology landscape, reflecting both companies' commitment to advancing genetic medicine. As the transaction progresses towards its anticipated closing in 2026, it underscores the ongoing evolution of cancer treatment strategies and the broader implications for patient care in the oncology sector.